International opinion endorses the new leader of the leaders in hypertension : Sotacor.

Contributors

Bristol Laboratories

Publication/Creation

[1975?]

Persistent URL

https://wellcomecollection.org/works/z82nthep

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection 183 Euston Road London NW1 2BE UK T +44 (0)20 7611 8722 E library@wellcomecollection.org https://wellcomecollection.org




THE NEW LEADER OF THE LEADERS IN HYPERTENSION





A Product of BRISTOL Research



A purpose-structured molecule for predictable reduction of blood pressure.

The following points were highlighted at an International Symposium on "Clinical Advances in Beta-Adrenergic Blocking Therapy" held in Rome during May 1974.

AS EFFECTIVE AS METHYLDOPA FOR ALL GRADES OF HYPERTENSION

GIVES SMOOTH, GENTLE, CONTROLLED REDUCTION OF BLOOD PRESSURE

CONTROLS BLOOD PRESSURE EVEN DURING EXERCISE

EFFECTIVE WITH OR WITHOUT DIURETICS

EFFECTIVE IN CONVENIENT, SIMPLE B.I.D. DOSAGE

RESTORES A REMARKABLE FEELING OF WEILL-BEING IN MOST PATIENTS



BRISTOL

n

Bristol Laboratories Division of Bristol-Myers Co Ltd Stamford House, Langley, Slough SL3 6EB

:uonisod

*Trade Mark

* Trade Mark Bristol Laboratories, Division of Bristol-Myers Co. Ltd., Stamford House, Langley, Slough, SL3 6EB



= :ssauppe

:emen

Please send me full information on Solacor (solator hydrochloride)